SOURCE: ImmuCell Corporation

ImmuCell Corporation

April 14, 2015 10:57 ET

ImmuCell Announces New Bacteriocin Collaboration With the University of Massachusetts Amherst

PORTLAND, ME--(Marketwired - April 14, 2015) - ImmuCell Corporation (NASDAQ: ICCC) today announced that it has entered into an exclusive option agreement to license new bacteriocin technology from the University of Massachusetts Amherst. 

This technology, developed by Dr. Margaret Riley and her colleagues in the Department of Biology at UMass Amherst, focuses on bacteriocins with activity against Gram negative infections, for use in combating mastitis in dairy cattle. This will broaden the Company's pipeline of bacteriocin molecules to treat infections, providing alternatives to traditional antibiotics.

"We are committed to providing cattle producers and practitioners with novel approaches to treat infections with highly efficacious alternatives to traditional antibiotics," commented Joseph H. Crabb, ImmuCell's Vice President and Chief Scientific Officer. "Dr. Riley's lab has discovered new bacteriocins that, along with Mast Out®, have the potential to revolutionize the treatment of mastitis."

Dr. Riley, an internationally recognized researcher in bacteriocin biology, said, "I am delighted with our collaboration with ImmuCell, a company that shares our vision of a 21st century arsenal rich with drugs that target the infecting agents, while leaving the commensal microbiome intact and thus reducing the selective intensity for antibiotic resistance. ImmuCell is the only US-based biopharmaceutical company to offer bacteriocin-based veterinary products, providing them an exciting head start in the race to generate a more diverse and ecologically sound portfolio of alternatives to conventional broad spectrum antibiotics. We are pleased to have the opportunity to generate new bacteriocin drug candidates for their pipeline."

"We see this technology platform as a logical extension of the work we are doing with Nisin," commented Michael F. Brigham, President and Chief Executive Officer. "As our Mast Out® initiative approaches the end of the regulatory development process, this technology adds something with great potential to the front end of our product development pipeline."

About ImmuCell
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef cattle. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at our website, (http://www.immucell.com).

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis; future market share of and revenue generated by products still in development; future sources of financial support for our product development, manufacturing and marketing efforts; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the amount and timing of future investments in facility modifications and production equipment; the future adequacy of our working capital and the availability of third party financing; timing and future costs of a facility to produce the Drug Substance (active pharmaceutical ingredient) for Mast Out®; the timing and outcome of pending or anticipated applications for future regulatory approvals; future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; future realization of deferred tax assets; costs associated with sustaining compliance with cGMP regulations in our current operations and attaining such compliance for the facility to produce the Drug Substance for Mast Out®; factors that may affect the dairy and beef industries and future demand for our products; the cost-effectiveness of additional sales and marketing expenditures and resources; the accuracy of our understanding of our distributors' ordering patterns; anticipated changes in our manufacturing capabilities and efficiencies; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts" and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, alignment between our manufacturing resources and product demand, the uncertainties associated with product development and Drug Substance manufacturing, our potential reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities, currency fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors.

Contact Information

  • Contact:
    Michael F. Brigham
    President and CEO
    ImmuCell Corporation
    (207) 878-2770

    Joe Diaz
    Robert Blum
    Joe Dorame
    Lytham Partners, LLC
    (602) 889-9700
    Email contact